Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
OBSERVER CORPS REPORT – COUNTY COUNCIL – JUNE 30, 2026 The video of the full meeting may be seen at  Water Service Rates, ...